Sulfadoxine pyrimethamine (SP) — Competitive Intelligence Brief

Sulfadoxine pyrimethamine (SP) (Sulfadoxine pyrimethamine (SP)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic. Area: Infectious Diseases.

phase 3 Antibiotic Dihydropteroate synthase, Dihydrofolate reductase Infectious Diseases Small molecule

Target snapshot

Sulfadoxine pyrimethamine (SP) (Sulfadoxine pyrimethamine (SP)) — Menzies School of Health Research. Sulfadoxine pyrimethamine (SP) is a combination antibiotic that works by inhibiting the growth of bacteria by interfering with their ability to synthesize folic acid.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sulfadoxine pyrimethamine (SP) TARGET	Sulfadoxine pyrimethamine (SP)	Menzies School of Health Research	phase 3	Antibiotic	Dihydropteroate synthase, Dihydrofolate reductase
Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin	Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin	London School of Hygiene and Tropical Medicine	phase 3	Antimalarial	Dihydropteroate synthase, Dihydrofolate reductase, Heme detoxification pathway
SP + amodiaquine	SP + amodiaquine	London School of Hygiene and Tropical Medicine	phase 3	Antimalarial	Dihydropteroate synthase, Dihydrofolate reductase
Avelox	moxifloxacin	Bayer AG	marketed	Fluoroquinolone antibiotic (fourth-generation)	DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A	1999-12-10
Zithromax	azithromycin	Pfizer Inc.	marketed	Macrolide antibiotic (azalide)	Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor	1991-11-01
Cipro	ciprofloxacin	Bayer AG	marketed	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Rocephin	ceftriaxone	Generic (originally Roche)	marketed	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2029-04-21 — Cipro · 11369566 · Formulation · US
• 2029-04-21 — Cipro · 9603796 · Compound · US
• 2029-04-21 — Cipro · 9205048 · Method of Use · US
• 2029-12-11 — Cipro · 9233068 · Formulation · US
• 2030-04-27 — Cipro · 8318817 · Method of Use · US
• 2035-07-01 — Cipro · 9220796 · Formulation · US
• 2037-11-12 — Cipro · 11040004 · Method of Use · US
• 2038-11-27 — Cipro · 11246863 · Formulation · US

Sponsor landscape (Antibiotic class)

1. Bausch Health Americas, Inc. · 2 drugs in this class
2. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
3. BioVersys AG · 1 drug in this class
4. Bosnalijek D.D · 1 drug in this class
5. Capital Medical University · 1 drug in this class
6. Dr. Reddy's Laboratories Limited · 1 drug in this class
7. Incheon St.Mary's Hospital · 1 drug in this class
8. Jomaa Pharma GmbH · 1 drug in this class
9. King Abdulaziz University · 1 drug in this class
10. Menzies School of Health Research · 1 drug in this class